Table 2.
Distribution of localised versus metastatic RMS according to patient and clinical characteristics
| Localised RMS | Metastatic RMS | Missing | p Value* | |
|---|---|---|---|---|
| Sex (%) | ||||
| Male | 91 (87) | 14 (13) | 8 | 0.040/NS |
| Female | 70 (75) | 23 (25) | 4 | |
| Age (years) (%) | ||||
| <1 | 19 (91) | 2 (10) | 3 | NS/NS |
| 1–9 | 116 (80) | 29 (20) | 7 | |
| 10–14 | 26 (81) | 6 (19) | 2 | |
| Subtype (%) | ||||
| Embryonal RMS | 126 (88) | 18 (13) | 7 | <0.001/<0.001 |
| Alveolar RMS | 19 (56) | 15 (44) | 2 | |
| Other1 | 16 (80) | 4 (20) | 3 | |
| Tumour size (%) | ||||
| ≤5 cm | 75 (85) | 13 15) | 4 | NS/NS |
| >5 cm | 48 (74) | 17 (26) | 3 | |
| Missing | 38 | 7 | 5 | |
| Primary site (%) | ||||
| Favourable2 | 56 (90) | 6 (10) | 7 | 0.033/0.007 |
| Unfavourable3 | 104 (78) | 30 (22) | 4 | |
| Missing | 1 | 1 | 1 | |
*p Value determined by chi‐square test (missing information excluded/included). 1Includes patients diagnosed with RMS without further specified subtype, or missing information about subtype in the registry. 2Orbit, genitourinary (not bladder or prostate) and head and neck (nonparameningeal), 3Extremities, genitourinary (bladder or prostate), head and neck (parameningeal), and other sites.